Proposed Mode of Binding and Action of Positive Allosteric Modulators at Opioid Receptors

Available crystal structures of opioid receptors provide a high-resolution picture of ligand binding at the primary (“orthosteric”) site, that is, the site targeted by endogenous ligands. Recently, positive allosteric modulators of opioid receptors have also been discovered, but their modes of binding and action remain unknown. Here, we use a metadynamics-based strategy to efficiently sample the binding process of a recently discovered positive allosteric modulator of the δ-opioid receptor, BMS-986187, in the presence of the orthosteric agonist SNC-80, and with the receptor embedded in an explicit lipid–water environment. The dynamics of BMS-986187 were enhanced by biasing the potential acting on the ligand–receptor distance and ligand–receptor interaction contacts. Representative lowest-energy structures from the reconstructed free-energy landscape revealed two alternative ligand binding poses at an allosteric site delineated by transmembrane (TM) helices TM1, TM2, and TM7, with some participation of TM6. Mutations of amino acid residues at these proposed allosteric sites were found to either affect the binding of BMS-986187 or its ability to modulate the affinity and/or efficacy of SNC-80. Taken together, these combined experimental and computational studies provide the first atomic-level insight into the modulation of opioid receptor binding and signaling by allosteric modulators.

[1]  M. Parrinello,et al.  Crystal structure and pair potentials: A molecular-dynamics study , 1980 .

[2]  S. Nosé,et al.  Constant pressure molecular dynamics for molecular systems , 1983 .

[3]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[4]  Claes Wahlestedt,et al.  Involvement of Trp-284, Val-296, and Val-297 of the Human δ-Opioid Receptor in Binding of δ-Selective Ligands* , 1996, The Journal of Biological Chemistry.

[5]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997 .

[6]  C. Wahlestedt,et al.  Novel “Restoration of Function” Mutagenesis Strategy to Identify Amino Acids of the δ-Opioid Receptor Involved in Ligand Binding* , 1997, The Journal of Biological Chemistry.

[7]  A. Christopoulos Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. , 1998, Trends in pharmacological sciences.

[8]  A. Laio,et al.  Escaping free-energy minima , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  H. Schiöth,et al.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.

[10]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[11]  A. Laio,et al.  Efficient reconstruction of complex free energy landscapes by multiple walkers metadynamics. , 2006, The journal of physical chemistry. B.

[12]  C. Tränkle,et al.  Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[13]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[14]  Jeremy R. Greenwood,et al.  Epik: a software program for pKa prediction and protonation state generation for drug-like molecules , 2007, J. Comput. Aided Mol. Des..

[15]  P. Sexton,et al.  Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. , 2007, Trends in pharmacological sciences.

[16]  C. Langmead,et al.  Structure-Function Studies of Allosteric Agonism at M2 Muscarinic Acetylcholine Receptors , 2007, Molecular Pharmacology.

[17]  M. Parrinello,et al.  Well-tempered metadynamics: a smoothly converging and tunable free-energy method. , 2008, Physical review letters.

[18]  Massimiliano Bonomi,et al.  PLUMED: A portable plugin for free-energy calculations with molecular dynamics , 2009, Comput. Phys. Commun..

[19]  Davide Provasi,et al.  Exploring molecular mechanisms of ligand recognition by opioid receptors with metadynamics. , 2009, Biochemistry.

[20]  P. Sexton,et al.  Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties , 2010, Neuropsychopharmacology.

[21]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[22]  L. Devi,et al.  Structural biology: How opioid drugs bind to receptors , 2012, Nature.

[23]  Ying Xia,et al.  Current research on opioid receptor function. , 2012, Current drug targets.

[24]  Bryan L. Roth,et al.  Structure of the human kappa opioid receptor in complex with JDTic , 2012, Nature.

[25]  Aashish Manglik,et al.  Structure of the δ-opioid receptor bound to naltrindole , 2012, Nature.

[26]  O. Levran,et al.  Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. , 2012, The Journal of clinical investigation.

[27]  L. Pardo,et al.  Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.

[28]  Bryan L. Roth,et al.  Structure of the Nociceptin/Orphanin FQ Receptor in Complex with a Peptide Mimetic , 2012, Nature.

[29]  Jonathan A. Javitch,et al.  Discovery of a Novel Selective Kappa-Opioid Receptor Agonist Using Crystal Structure-Based Virtual Screening , 2013, J. Chem. Inf. Model..

[30]  Marta Filizola,et al.  Grand opening of structure-guided design for novel opioids. , 2013, Trends in pharmacological sciences.

[31]  M. Banks,et al.  Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor , 2013, Proceedings of the National Academy of Sciences.

[32]  B. Kieffer,et al.  Opioid receptors: distinct roles in mood disorders , 2013, Trends in Neurosciences.

[33]  Albert C. Pan,et al.  Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs , 2013, Nature.

[34]  G. Pasternak,et al.  Mechanistic Insights into the Allosteric Modulation of Opioid Receptors by Sodium Ions , 2014, Biochemistry.

[35]  G. Pasternak Opiate pharmacology and relief of pain. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Banks,et al.  Identification of Selective Agonists and Positive Allosteric Modulators for µ- and δ-Opioid Receptors from a Single High-Throughput Screen , 2014, Journal of biomolecular screening.

[37]  Pankaj R. Daga,et al.  Structure-Based Virtual Screening of the Nociceptin Receptor: Hybrid Docking and Shape-Based Approaches for Improved Hit Identification , 2014, J. Chem. Inf. Model..

[38]  Bryan L. Roth,et al.  Molecular control of δ-opioid receptor signalling , 2014, Nature.

[39]  J. Traynor,et al.  Positive allosteric modulators of the μ‐opioid receptor: a novel approach for future pain medications , 2015, British journal of pharmacology.

[40]  Arthur Christopoulos,et al.  Novel Allosteric Modulators of G Protein-coupled Receptors* , 2015, The Journal of Biological Chemistry.

[41]  Anton Barty,et al.  Structural basis for bifunctional peptide recognition at human δ-Opioid receptor , 2015, Nature Structural &Molecular Biology.

[42]  Kathryn E. Livingston,et al.  Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor. , 2015, Journal of medicinal chemistry.

[43]  M. Parrinello,et al.  A time-independent free energy estimator for metadynamics. , 2015, The journal of physical chemistry. B.

[44]  Davide Provasi,et al.  The Dynamic Process of Drug-GPCR Binding at Either Orthosteric or Allosteric Sites Evaluated by Metadynamics. , 2015, Methods in molecular biology.